A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada (ScreenX)
Status: Recruiting
Location: See all (13) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, as per provincial reimbursement criteria
• Adult patients at the time of informed consent signature
• Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
• Residents of Canada
Locations
Other Locations
Canada
Novartis Investigative Site
RECRUITING
Fredericton
Novartis Investigative Site
RECRUITING
Hamilton
Novartis Investigative Site
RECRUITING
Hamilton
Novartis Investigative Site
RECRUITING
Hamilton
Novartis Investigative Site
RECRUITING
Kelowna
Novartis Investigative Site
RECRUITING
Markham
Novartis Investigative Site
RECRUITING
Québec
Novartis Investigative Site
RECRUITING
Richmond Hill
Novartis Investigative Site
RECRUITING
Saskatoon
Novartis Investigative Site
RECRUITING
Saskatoon
Novartis Investigative Site
RECRUITING
Ste-foy
Novartis Investigative Site
RECRUITING
Stoney Creek
Novartis Investigative Site
RECRUITING
Waterloo
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
novartis.email@novartis.com
Time Frame
Start Date: 2025-01-23
Estimated Completion Date: 2026-08-31
Participants
Target number of participants: 502
Treatments
Other: PEST Screening group
When visiting their dermatologists, all eligible patients with moderate-to-severe plaque psoriasis (PsO) eligible for treatment with biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) will be screened for psoriatic arthritis (PsA) using PEST+pictures+2, a variation of the PEST screening tool.~The PEST+pictures+2 is made up of 3 components:~1. Psoriasis Epidemiology Screening Tool (PEST) consisting of 5 simple questions~2. PEST+2 refers to the PEST modified with two additional questions (Do you have morning stiffness that lasts for more than one (1) hour? Do you wake up at night because of low back or buttock pain?), AND~3. PEST+pictures which provides an opportunity for patients to modify their answers to PEST questions 1, 3, and 5 by presenting them with pictures of swollen joints, fingernail pitting, and swollen fingers and toes.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals